

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 65005

**Title:** Cellular targets in diabetic retinopathy therapy

**Reviewer's code:** 05928676

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2021-02-26

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-03-15 14:38

**Reviewer performed review:** 2021-03-24 15:06

**Review time:** 9 Days

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

This manuscript provides a perspective on potential targets for diabetic retinopathy. The manuscript is generally well-written and does an adequate job of presenting rationale for the pursuit of covered targets. The article is suitable for publication in World Journal of Diabetes pending minor revisions. Requested revisions are indicated below: The authors either need to include other targets that are perhaps more advanced and/or validated (e.g., PPARs) or they need to narrow the title of the perspective to indicate that it is focused on redox related pathways. Regardless, this reviewer suggests the authors include a discussion on PPARs as they fit with the topic and are too important to leave out. A good place to tie them in may be when discussing WNT signaling, as it's known that PPAR agonism, for example, results in WNT signaling inhibition. The authors should include graphics to help indicate how pathways discussed lead to disease and to illustrate places of intervention. Inclusion of such visuals would enhance the accessibility of this article tremendously. The authors should include a summary table/graphic towards the end to capture the targets discussed. Once again, this would be very helpful to the reader and will likely lead to a higher impact reference for researchers. The authors should include a section that expands upon the challenges associated with the targets proposed/covered. Likewise, a section highlighting the challenges of ocular drug discovery in general is warranted. Is it possible for these targets to be accessed via systemic administration to alleviate complications with current approaches? Please proofread carefully, a number of typos and sentence structure errors are scattered throughout.